Newsfiscal.ai
HC Wainwright & Co. Initiates Coverage of MiNK Therapeutics with Buy Rating
· Published
Article summary
HC Wainwright & Co. has assumed coverage of MiNK Therapeutics, assigning the stock a 'Buy' rating and a price target of $38.
An excerpt from the original article.Analyzed by WAPE AI.
Preparing English content…


Comments —
Loading comments…